TY - JOUR
T1 - Reduced Antibody Acquisition with Increasing Age following Vaccination with BNT162b2
T2 - Results from Two Longitudinal Cohort Studies in The Netherlands
AU - van den Hoogen, Lotus Leonie
AU - Boer, Mardi
AU - Postema, Abigail
AU - de Rond, Lia
AU - de Zeeuw-Brouwer, Mary lène
AU - Pronk, Inge
AU - Wijmenga-Monsuur, Alienke Jentien
AU - Bijvank, Elske
AU - Kruiper, Caitlyn
AU - Beckers, Lisa
AU - Maurik, Marjan Bogaard van
AU - Zutt, Ilse
AU - van Vliet, Jeffrey
AU - van Bergen, Rianne
AU - Kuijer, Marjan
AU - Smits, Gaby
AU - Verschuren, W. M.Monique
AU - Picavet, H. Susan J.
AU - van der Klis, Fiona Regina Maria
AU - den Hartog, Gerco
AU - van Binnendijk, Robert Samuel
AU - Buisman, Anne Marie
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2022/9
Y1 - 2022/9
N2 - Vaccine-induced protection against severe COVID-19, hospitalization, and death is of the utmost importance, especially in the elderly. However, limited data are available on humoral immune responses following COVID-19 vaccination in the general population across a broad age range. We performed an integrated analysis of the effect of age, sex, and prior SARS-CoV-2 infection on Spike S1-specific (S1) IgG concentrations up to three months post-BNT162b2 (Pfizer/BioNTech; Comirnaty) vaccination. In total, 1735 persons, eligible for COVID-19 vaccination through the national program, were recruited from the general population (12 to 92 years old). Sixty percent were female, and the median vaccination interval was 35 days (interquartile range, IQR: 35–35). All participants had seroconverted to S1 one month after two vaccine doses. S1 IgG was higher in participants with a history of SARS-CoV-2 infection (median: 4535 BAU/mL, IQR: 2341–7205) compared to infection-naive persons (1842 BAU/mL, 1019–3116), p < 0.001. In infection-naive persons, linear mixed effects regression showed a strong negative association between age and S1 IgG (p < 0.001) across the entire age range. Females had higher S1 IgG than males (p < 0.001). In persons with an infection history, age nor sex was associated with S1 IgG concentrations. The lower magnitude of S1 antibodies in older persons following COVID-19 vaccination will affect long-term protection.
AB - Vaccine-induced protection against severe COVID-19, hospitalization, and death is of the utmost importance, especially in the elderly. However, limited data are available on humoral immune responses following COVID-19 vaccination in the general population across a broad age range. We performed an integrated analysis of the effect of age, sex, and prior SARS-CoV-2 infection on Spike S1-specific (S1) IgG concentrations up to three months post-BNT162b2 (Pfizer/BioNTech; Comirnaty) vaccination. In total, 1735 persons, eligible for COVID-19 vaccination through the national program, were recruited from the general population (12 to 92 years old). Sixty percent were female, and the median vaccination interval was 35 days (interquartile range, IQR: 35–35). All participants had seroconverted to S1 one month after two vaccine doses. S1 IgG was higher in participants with a history of SARS-CoV-2 infection (median: 4535 BAU/mL, IQR: 2341–7205) compared to infection-naive persons (1842 BAU/mL, 1019–3116), p < 0.001. In infection-naive persons, linear mixed effects regression showed a strong negative association between age and S1 IgG (p < 0.001) across the entire age range. Females had higher S1 IgG than males (p < 0.001). In persons with an infection history, age nor sex was associated with S1 IgG concentrations. The lower magnitude of S1 antibodies in older persons following COVID-19 vaccination will affect long-term protection.
KW - antibody
KW - BNT162b2
KW - COVID-19
UR - http://www.scopus.com/inward/record.url?scp=85138605034&partnerID=8YFLogxK
U2 - 10.3390/vaccines10091480
DO - 10.3390/vaccines10091480
M3 - Article
AN - SCOPUS:85138605034
SN - 2076-393X
VL - 10
JO - Vaccines
JF - Vaccines
IS - 9
M1 - 1480
ER -